First assessment of covid-19 vaccine response in a population at risk

ConclusionsThis study analyses neutralizing antibodies, which should prevent the virus from binding to target cells via spike protein. According to literature, immunological response to vaccine presents a great variability of antibodies level in the study population. However, no significantly correlations were found between the available variables. Preliminary data show the presence of a very intense antibody response after active vaccine immunization both in subjects with previous infection and in the rest of the study population.Key messagesCovid-19 vaccine response in a population at risk.Differences between subjects with or without a confirmed previous infection.
Source: The European Journal of Public Health - Category: General Medicine Source Type: research

Related Links:

NEW BRUNSWICK, N.J., DECEMBER 5, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced preliminary results from an independent study, including a subset of participants from the Janssen-sponsored COV2008 study, conducted by Dan Barouch, M.D., Ph.D., et al. of Beth Israel Deaconess Medical Center (BIDMC), which showed that a booster shot of the Johnson &Johnson COVID-19 vaccine (Ad26.COV2.S), administered at six months after a two-dose primary regimen of BNT162b2, increased both antibody and T-cell responses. These results demonstrate the potential benefits of heterologous boosting (mix-and-match)....
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve as a global health crisis. Although highly effective vaccines have been developed, non-pharm...
Source: BMC Public Health - Category: Consumer Health News Authors: Tags: Study protocol Source Type: research
Rich nations are again raising barriers to ending the pandemic – politicians, globally, must follow the science and act togetherDr Ayoade Olatunbosun-Alakija is the co-chair of the African Union ’s Africa Vaccine Delivery AllianceThe advent of the Omicron variant has given us a glimpse of an alternative future in which, had the Sars-CoV-2 virus been initially identified in Africa in early 2020, the world would have maybe locked Africa away. There would have been no emergency funding for vaccine development, limited global attention, and Africa would have become known as the continent of Covid.We may never know ...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Africa Coronavirus World news Science Source Type: news
CONCLUSIONS: In Saudi Arabia, Pfizer/BioNTech and Oxford/AstraZeneca vaccinations significantly reduced the number of SARS-CoV-2 cases and deaths after the vaccination compared to the period before the vaccination campaign at country levels. The study findings demonstrate that vaccination and adherence to nonpharmaceutical intervention can better control the COVID-19 pandemic.PMID:34859883 | DOI:10.26355/eurrev_202111_27271
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Source Type: research
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7162-7184. doi: 10.26355/eurrev_202111_27270.ABSTRACTThe last two decades have witnessed the emergence of three deadly coronaviruses (CoVs) in humans: severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are still no reliable and efficient therapeutics to manage the devastating consequences of these CoVs. Of these, SARS-CoV-2, the cause of the currently ongoing coronavirus disease 2019 (COVID-19) pandemic, has posed great global health concerns. The...
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Source Type: research
CONCLUSIONS: In Saudi Arabia, Pfizer/BioNTech and Oxford/AstraZeneca vaccinations significantly reduced the number of SARS-CoV-2 cases and deaths after the vaccination compared to the period before the vaccination campaign at country levels. The study findings demonstrate that vaccination and adherence to nonpharmaceutical intervention can better control the COVID-19 pandemic.PMID:34859883 | DOI:10.26355/eurrev_202111_27271
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Source Type: research
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7162-7184. doi: 10.26355/eurrev_202111_27270.ABSTRACTThe last two decades have witnessed the emergence of three deadly coronaviruses (CoVs) in humans: severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are still no reliable and efficient therapeutics to manage the devastating consequences of these CoVs. Of these, SARS-CoV-2, the cause of the currently ongoing coronavirus disease 2019 (COVID-19) pandemic, has posed great global health concerns. The...
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Source Type: research
CONCLUSIONS: In Saudi Arabia, Pfizer/BioNTech and Oxford/AstraZeneca vaccinations significantly reduced the number of SARS-CoV-2 cases and deaths after the vaccination compared to the period before the vaccination campaign at country levels. The study findings demonstrate that vaccination and adherence to nonpharmaceutical intervention can better control the COVID-19 pandemic.PMID:34859883 | DOI:10.26355/eurrev_202111_27271
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Authors: Source Type: research
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7162-7184. doi: 10.26355/eurrev_202111_27270.ABSTRACTThe last two decades have witnessed the emergence of three deadly coronaviruses (CoVs) in humans: severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are still no reliable and efficient therapeutics to manage the devastating consequences of these CoVs. Of these, SARS-CoV-2, the cause of the currently ongoing coronavirus disease 2019 (COVID-19) pandemic, has posed great global health concerns. The...
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Authors: Source Type: research
CONCLUSIONS: In Saudi Arabia, Pfizer/BioNTech and Oxford/AstraZeneca vaccinations significantly reduced the number of SARS-CoV-2 cases and deaths after the vaccination compared to the period before the vaccination campaign at country levels. The study findings demonstrate that vaccination and adherence to nonpharmaceutical intervention can better control the COVID-19 pandemic.PMID:34859883 | DOI:10.26355/eurrev_202111_27271
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Authors: Source Type: research
More News: Allergy & Immunology | Coronavirus | COVID-19 | General Medicine | International Medicine & Public Health | Nurses | Nursing | Pandemics | Respiratory Medicine | SARS | Statistics | Study | Vaccines